Clinical Trial News and Research

RSS

Catalyst Pharmaceutical Partners first-quarter net loss decreases to $0.06 per basic and diluted share

Catalyst Pharmaceutical Partners, Inc. today announced its financial results for the three month period ended March 31, 2010. The Company reported a net loss of $1,045,043, or $0.06 per basic and diluted share, compared to a net loss of $3,031,201, or $0.22 per basic and diluted share, for the same period in 2009.

18 May 2010

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

Tengion Inc. today reported its financial results for the quarter ended March 31, 2010 and provided a corporate and clinical development update.

18 May 2010

EDAP first-quarter revenue decreases to EUR 4.3 million

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today financial results for the first quarter ended March 31, 2010.

18 May 2010

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.

18 May 2010

Acurian announces opted-in database for minority patient recruitment

Acurian, a leader in clinical trial patient recruitment and retention, announced today that its opted-in patient database is an effective resource for reaching minority populations for patient recruitment. Increasing minority participation is crucial for trial success and regulatory approval, especially for therapies intended to treat diseases with high incidence and prevalence rates among minorities.

18 May 2010

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

18 May 2010

IDEV launches SUPERA VERITAS Peripheral Vascular System in Europe

IDEV Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced the European launch of the SUPERA VERITAS™ Peripheral Vascular System, a novel and innovative stent delivery system designed to be reliable, easy to use and precise. The SUPERA VERITAS system was formally launched in the first quarter of 2010 at the Leipzig Interventional Course (LINC) 2010 conference in Leipzig, Germany.

18 May 2010

Cancer Research UK launches new cancer centre in Leeds

LEEDS today joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

18 May 2010

Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine

For more than a decade, researchers and advocates have marked HIV Vaccine Awareness Day with varying degrees of hope, cynicism and despair. This year, in large part because of the results of the Thai Prime-Boost vaccine study, there is greater cause for hope than ever before and a renewed sense of urgency to transform this hope into a reality.

18 May 2010

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

Patients who received hypofractionated stereotactic radiotherapy for their recurrent brain cancers lived longer lives, according to researchers at Thomas Jefferson University.

18 May 2010

Final data from Open-Label studies of Cinryze in patients with HAE now available

ViroPharma Incorporated today announced the availability of final data from Open-Label studies of Cinryze (C1 Esterase Inhibitor [Human]) in preventing and treating attacks of hereditary angioedema on the U.S. National Institutes of Health's online clinical trial registry, www.clinicaltrials.gov.

18 May 2010

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010.

18 May 2010

Echo Therapeutics first-quarter net loss increases to $1.9 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced financial results for the period ended March 31, 2010.

18 May 2010

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans.

17 May 2010

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (DCM). Treatment was performed by interventional cardiologist Timothy D. Henry, M.D., FACC, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, MN.

17 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.

17 May 2010

Soligenix first-quarter revenues decrease to $336,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010.

17 May 2010

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.

17 May 2010

Neovasc first-quarter revenues increase nearly 300% to $1.06 million

Neovasc Inc., today announced financial results for the three months ended March 31, 2009.

17 May 2010

Clinical Trial News and Research

Catalyst Pharmaceutical Partners first-quarter net loss decreases to $0.06 per basic and diluted share

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

EDAP first-quarter revenue decreases to EUR 4.3 million

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Acurian announces opted-in database for minority patient recruitment

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

IDEV launches SUPERA VERITAS Peripheral Vascular System in Europe

Cancer Research UK launches new cancer centre in Leeds

Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

Final data from Open-Label studies of Cinryze in patients with HAE now available

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Echo Therapeutics first-quarter net loss increases to $1.9 million

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Emisphere Technologies first-quarter net loss increases to $18.5 million

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

Soligenix first-quarter revenues decrease to $336,000

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

Neovasc first-quarter revenues increase nearly 300% to $1.06 million

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery